ClinicalTrials.gg
Not yet recruitingNCT07475559Updated Mar 16, 2026

JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors

A Phase 1 interventional study of JSKN016HC in Advanced Solid Tumor Malignancies, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase I, open-label, multicenter, first-in-human study to evaluate the safety, tolerability, PK/pharmacodynamic (PD) characteristics, and anti-tumor activity of JSKN016HC in subjects with advanced malignant solid tumors.

Read the detailed description

JSKN016HC is a subcutaneously injectable formulation of a bispecific ADC targeting HER3 and TROP2 (the main active ingredient is JSKN016).

This study will use i3+3 design for dose escalation, with a total of 4-7 dose cohorts designed. The starting dose is 4 mg/kg, Q2W. The dose cohorts and observation periods are defined in the Dose Escalation Table. During the study, necessary adjustments to the escalation dose and dosing interval may be made based on the obtained safety, PK, and other results.

During dose escalation, the SMC will conduct continuous safety assessments. The safety data for each dose cohort must be reviewed and a decision must be made by the SMC before dosing of the next dose cohort can begin. For Dose Cohort 2 (5 mg/kg Q2W), Dose Cohort 4 (7 mg/kg Q2W), and Dose Cohort 6 (9 mg/kg Q2W), the SMC may decide whether to skip these dose cohorts based on a comprehensive consideration of prior safety, PK (if available), and other data.

02

Conditions studied

  • Advanced Solid Tumor Malignancies
03

In context

Lead sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd is the lead sponsor of 38 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are able to understand the form (ICF), voluntarily participate, and sign the ICF;
  2. Patients who are ≥18 years of age on the day of signing the informed consent form, male or female;
  3. Performance Status (ECOG PS) score of 0 or 1;
  4. ≥ 3 months;
  5. At least one non-cranial at baseline according to 1.1 criteria. Target lesions must not have received prior local therapy (e.g., radiotherapy), or there must be evidence of disease progression in the lesion after local therapy;
  6. Patients with and/or cytologically confirmed advanced unresectable or epithelial-derived malignant tumors who have failed prior standard of care (disease progression, intolerance, or inaccessibility of standard of case);
  7. Adequate organ function (results from within 7 days before the first dose are required for the following laboratory tests; echocardiogram results from within 28 days before the first dose are acceptable):

    1. Bone marrow function (no whole blood or blood component transfusions within 14 days before the first dose; no use of haematopoietic growth factors within 7 days before the first dose): ≥1.5×109/L; ≥90 g/L; count ≥100×109/L;
    2. Liver function (based on the normal values of each clinical study site): Total ≤ 1.5 × ; and AST ≤ 3×ULN (≤ 5×ULN for subjects with metastases to liver); albumin ≥ 28 g/L;
    3. Renal function: Blood creatinine ≤ 1.5 ×ULN, or (Ccr) ≥ 60 mL/min as calculated by the Cockcroft-Gault formula; urine protein ≤ 1+ or 24-hour (h) quantitative urine protein \< 1.0 g;
    4. Coagulation function: (INR) or prothrombin time (PT) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5×ULN;
    5. Cardiac function: (LVEF) ≥ 50% (by echocardiogram);
  8. Female patients of or male patients with partners of childbearing potential must agree to use highly effective from the time of signing the ICF until 24 weeks after the last dose. Female patients of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose;
  9. Patients who are able and willing to comply with the visits, treatment plan, laboratory tests, and other study-related procedures specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Presence of to brainstem, metastasis to meninges, metastasis to spinal cord or compression, or a history of carcinomatous meningitis; presence of active . Note: a. For patients with brain metastasis previously treated with local therapy (e.g., surgery, radiotherapy): patients who are clinically stable for at least 4 weeks before the first dose (imaging examination shows stable lesions, no new neurological symptoms, no evidence of new or enlarging pre-existing brain metastasis), and have not required or anticonvulsants for at least 2 weeks are eligible for enrollment; b. For patients with brain metastasis not previously treated with local therapy: patients with no neurological symptoms related to brain metastasis, not requiring corticosteroid treatment, no significant oedema around brain metastasis, and with all brain metastases \< 1.5 cm are eligible for enrollment;
  2. Imaging during the screening period shows the tumor invades or compresses the surrounding vital organs (e.g., heart and pericardium, trachea, oesophagus, superior vena cava, etc.) or risk of developing oesophageal-tracheal fistula or oesophageal-pleural fistula;
  3. Insufficient for prior therapies before the first dose:

    1. Receipt of any drug within 28 days before dosing;
    2. Receipt of other anti-tumor therapy within 28 days before dosing or within 5 half-lives of a prior anti-tumor drug (whichever is shorter, but at least 14 days is required);
    3. Receipt of Chinese herbal medicines or proprietary Chinese medicines with a clear anti-tumor indication within 14 days before dosing;
    4. Receipt of non-specific immunomodulatory therapy (e.g., interleukin, interferon, thymosin, tumor necrosis factor, etc.) within 14 days before the first dose;
    5. Requirement for continuous treatment with glucocorticoids (> 10 mg/day prednisone, or equivalent dose of other glucocorticoids) or for 7 days within 14 days before the first dose; excluding inhaled or topical steroids, or physiological replacement doses of steroids for adrenal insufficiency; short-term (≤7 days) use of glucocorticoids for prophylaxis (e.g., for contrast media allergy) or treatment of non- conditions (e.g., delayed-type due to allergen exposure) is permitted;
    6. Receipt of local palliative therapy within 14 days before dosing;
    7. Major surgery within 28 days before dosing (e.g., major abdominal or thoracic surgery; minor procedures such as diagnostic aspiration, infusion device implantation, or biliary stent placement are not included), or anticipation of requiring major surgery during the study;
    8. Receipt of a within 30 days before the first dose, or planned receipt of a live vaccine during the study;
  4. Prior treatment with an ADC containing a topoisomerase I inhibitor (e.g., DS-8201, HER3-DXd, DS-1062, etc);
  5. Concurrent other malignant tumor within 5 years before dosing, excluding cured cutaneous squamous cell carcinoma, basal cell carcinoma, non-muscle invasive bladder cancer, and in situ prostate/cervical/breast cancer/ papillary thyroid carcinoma, etc;
  6. Presence or history of the following lung disorders that cause severe impairment of respiratory function:

    1. Active or severe structural lung disorder: including pulmonary embolism diagnosed within 6 months before the first dose, uncontrolled severe asthma (e.g., requiring continuous systemic steroid therapy or frequent acute exacerbations), severe , or severe restrictive pulmonary disease (e.g., severe pulmonary fibrosis, deformity thorax), etc.;
    2. Systemic diseases with pulmonary involvement: autoimmune diseases, connective tissue diseases, or inflammatory diseases (e.g., rheumatoid arthritis, sicca syndrome, sarcoidosis, etc.) causing significant impairment of respiratory function;
    3. Pulmonary resection: prior pneumonectomy;
  7. Current interstitial lung disease (ILD) or non-infectious pneumonia (e.g., idiopathic pulmonary fibrosis, radiation pneumonitis, etc.) requiring systemic glucocorticoid or other immunosuppressant therapy;
  8. gastrointestinal abnormalities, including but not limited to:

    1. Intestinal obstruction or signs and symptoms of intestinal obstruction within 6 months before the first dose, but screening is permissible if surgery has been performed and the obstruction is completely resolved (patients who have previously received an intestinal stent that has not been removed by the screening period are not allowed to enroll);
    2. History of gastrointestinal perforation, intestinal fistula, intra-abdominal abscess, and non-gastrointestinal fistula (e.g., oesophageal-tracheal fistula) within 6 months before the first dose;
    3. Gastrointestinal haemorrhage of ≥ Grade 3 ( v5.0) within 6 months before the first dose, or gastrointestinal haemorrhage within 1 month (including melaena, haematochezia, etc.; patients confirmed to have haemorrhoidal haemorrhage or only presenting with faecal occult blood positive are eligible for enrollment);
  9. Active autoimmune disease requiring systemic treatment within the past two years (e.g., treatment with disease-modifying drugs, corticosteroids, immunosuppressants). Note: Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a systemic treatment;
  10. Presence of serous cavity effusion (e.g., pleural effusion, pericardial effusion, ascites) that is clinically symptomatic or requires repeated drainage(>1 time/week), or has required drainage within 14 days before the first dose;
  11. Presence of any of the following cardiovascular or cerebrovascular disorders or risk factors:

    1. Myocardial infarction, unstable angina, acute or persistent myocardial ischaemia, Grade ≥3 cardiac failure ( classification), symptomatic or poorly controlled severe arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, Torsades de Pointes, complete left or right bundle branch block, history of second- or third-degree heart block, etc.), cerebrovascular accident, , or other severe cardiovascular or cerebrovascular disorders within 6 months before the first dose;
    2. Any arterial thromboembolic event or venous thromboembolic event of ≥ Grade 3 (CTCAE v5.0) within 6 months before the first dose;
    3. Presence of major vascular diseases that may be life-threatening or require surgery within 6 months, such as aortic aneurysm, aortic dissection, or severe internal carotid artery stenosis;
    4. Risk of prolongation or severe arrhythmia, including baseline QT interval corrected by Fridericia's formula (QTcF) > 470 ms, hypokalaemia, long QT syndrome, etc.;
    5. Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg);
    6. Presence of moderate to severe pulmonary arterial hypertension;
  12. Uncontrolled infection, including but not limited to the following:

    1. Active or infection. HBsAg-positive patients are required to undergo HBV-DNA testing; if HBV-DNA is above the lower limit of detection of the local laboratory, they will be excluded. For HBsAg-positive patients, enrollment is permitted if HBV-DNA is below the lower limit of detection after receiving antiviral therapy, and anti-HBV therapy should be continued after subsequent treatment. HCV-Ab-positive patients are eligible for enrollment if HCV-RNA test is negative;
    2. Severe infection within 4 weeks before the first dose, including but not limited to comorbidities requiring hospitalisation, sepsis, or severe pneumonia; active infection requiring systemic anti-infective drug therapy within 2 weeks before the first dose;
    3. History of immunodeficiency, positive test for (HIV), or history of acquired immunodeficiency syndrome (AIDS);
    4. Known active tuberculosis;
    5. Active syphilis;
  13. Toxicity from prior anti-tumor therapy has not resolved to ≤ Grade 1 (CTCAE v5.0) or the level specified in the inclusion/exclusion criteria. Note: Patients with chronic, stable Grade 2 toxicity that the investigator considers related to prior anti-tumor therapy may be enrolled after discussion with the sponsor and medical monitor (defined as stable toxicity severity, CTCAE Grade ≤2, within 3 months before the first dose), such as: chemotherapy-induced neurotoxicity, alopecia, skin hyperpigmentation, fatigue, endocrine toxicity from prior immunotherapy (e.g., thyroid dysfunction, diabetes mellitus, adrenal insufficiency);
  14. History of prior allogeneic bone marrow or organ transplant;
  15. Known hypersensitivity to any component of the investigational product; history of severe allergic reactions to other antibody-based drugs;
  16. History of severe xerophthalmia, severe meibomian gland disease and/or blepharitis, keratopathy causing incurable or delayed healing of the subject's cornea, or maculopathy;
  17. Women who are pregnant and/or breastfeeding, or who plan to become pregnant during the study;
  18. Known history of psychiatric illness, drug abuse, alcoholism, etc., or other conditions that, in the investigator's opinion, would interfere with the safety or compliance of drug therapy in this study;
  19. Prior or current presence of any other disease, treatment, or abnormal laboratory test that might confound the study results, interfere with the subject's full participation in the study, or for which participation in the study might not be in the subject's best interest;
  20. Presence of local or systemic diseases caused by non-malignant tumor, or diseases or symptoms secondary to the tumor, which may lead to higher medical risk and/or uncertainty in survival assessment, such as tumor-related leukaemoid reaction (white blood cell count >20×109/L), cachexia, etc.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    This study will use i3+3 design for dose escalation, with a total of 4-7 dose cohorts designed. The starting dose is 4 mg/kg, Q2W. The dose cohorts and observation periods are defined in the Dose Escalation Table. During the study, necessary adjustments to the escalation dose and dosing interval may be made based on the obtained safety, PK, and other results.

    Drug: JSKN016HC

Interventions

  • DrugJSKN016HC

    JSKN016HC is a subcutaneously injectable formulation of a bispecific ADC targeting HER3 and TROP2 (the main active ingredient is JSKN016).

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs) in each dose group of JSKN016HC

    DLTs are defined as side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.

    Time frame: Baseline up to 28 days after the first dose

  2. Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), etc., during treatment with JSKN016HC;

    Clinically significant changes in physical examination findings, vital sign measurements, standard clinical laboratory parameters, 12-lead electrocardiogram (ECG) parameters, ECHO cardiography or multiple-gated acquisition (MUGA) scan findings will be recorded as AEs.

    Time frame: Postdose of last participant up to 2 year

  3. MTD and/or RP2D of JSKN016HC.

    To determine MTD/RP2D of JSKN016HC.

    Time frame: Postdose of last participant up to 2 year

Secondary outcomes

  1. Objective response rate (ORR)

    Objective response rate (ORR) by investigators' review was defined as the proportion of participants who achieve either complete response \[CR\] or partial response \[PR\] per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: From 6 weeks postdose of last participant up to 2 years

  2. Duration Of Response (DoR) of JSKN016HC

    DOR is defined as the time from assessment of complete response or partial response to disease progression or death in patients who achieve complete or partial response.

    Time frame: Postdose of last participant up to 2 years

  3. Progression-Free Survival (PFS) Following Treatment With JSKN016HC in Participants

    PFS by investigator assessment is defined as the time from first dose of study drug to disease progression(as per RECIST v1.1) or death

    Time frame: Postdose of last participant up to 2 years

  4. 6-month and 12-month overall survival (OS) rates

    The 6-month and 12-month Overall Survival (OS) rate is typically estimated using the Kaplan-Meier method, which calculates the probability of survival at the 6-month time point while accounting for censored data.

    Time frame: Postdose of last participant up to 2 years

  5. Maximum concentration (Cmax) of JSKN016HC

    JSKN016HC , total antibody (Tab) , payload of JSKN016HC

    Time frame: Postdose of last participant up to 2 year

  6. Time at which Cmax is reached (Tmax)

    JSKN016HC, total antibody (Tab) , payload of JSKN016HC

    Time frame: Postdose of last participant up to 2 year

  7. Area under the drug concentration-time curve (AUC) to the last observable concentration (AUClast)

    JSKN016HC, total antibody (Tab) , payload of JSKN016HC

    Time frame: Postdose of last participant up to 2 year

  8. Clinical Benefit Rate (CBR)

    The proportion of participants in the study who achieve a confirmed CR, PR, or SD lasting at least 24 weeks, as assessed based on RECIST v1.1 criteria.

    Time frame: Postdose of last participant up to 2 years

  9. Disease Control Rate (DCR)

    The proportion of participants in the study who achieve a confirmed CR, PR, or SD as assessed based on RECIST v1.1 criteria

    Time frame: Postdose of last participant up to 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Jul 2028, 28 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 16, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 1, 2028
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07475559
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Mar 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion